Macular Edema News and Research

RSS

New micro-pump technology may offer promising alternative to eye drops for glaucoma patients

It is no secret that the issues associated with current glaucoma medications can be problematic. Systemic medications carry the risk of side effects, while the current medical treatment of choice, eye drops, has its own drawbacks.

2 Mar 2017

Red color channel can help detect diabetic macular edema in racial/ethnic minority patients

In photographs of the eye used to screen for diabetes-related eye disease, separating out the red color channel can help show some abnormalities—especially in racial/ethnic minority patients, suggests a study in the February issue of Optometry and Vision Science, official journal of the American Academy of Optometry.

6 Feb 2017

Increased growth factor protects retinal blood vessels in animal models with diabetes

Researchers from the Schepens Eye Research Institute of Massachusetts Eye and Ear have shown that a slight increase in transforming growth factor beta (TGF-β), which is present in preclinical animal models with diabetic eye disease, protects retinal blood vessels from damage that commonly occurs in the early stages of the disease.

2 Feb 2017

Joslin scientists suggest new approach to improve stroke therapy

The standard of care for treating strokes caused by blood clots involves the therapeutic infusion of tissue plasminogen activator (tPA), which can help to dissolve the clots and restore blood flow.

27 Jan 2017

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease, today announces that the first patient has been enrolled in its Phase II CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR).

13 Jan 2016

New study reveals better treatment options for proliferative diabetic retinopathy

This National Diabetes Month, there is some good news for people with eye complications from diabetes. Earlier this month, a network of researchers supported by the National Eye Institute (NEI) found that the drug Lucentis (ranibizumab) can be highly effective for treating proliferative diabetic retinopathy, an eye disease that can occur as a complication of diabetes.

20 Nov 2015

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

In a randomized clinical trial of more than 300 participants, researchers from Johns Hopkins and elsewhere have found that ranibizumab — a drug most commonly used to treat retinal swelling in people with diabetes — is an effective alternative to laser therapy for treating the most severe, potentially blinding form of diabetic retinal disease. Results of the government-sponsored study also show that the drug therapy carries fewer side effects than the currently used laser treatment.

17 Nov 2015

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Among patients with proliferative diabetic retinopathy, treatment with an injection in the eye of the drug ranibizumab resulted in visual acuity that was not worse than panretinal photocoagulation at 2 years, according to a study appearing in JAMA.

15 Nov 2015

Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

In the UK there are currently over 3.5 million people who have diabetes, with a growth rate exceeding 280,000 people per year. Diabetic retinopathy is the most common complication of diabetes.

19 Oct 2015

Allergan completes acquisition of AqueSys

Allergan plc, a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of AqueSys, Inc. a clinical-stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma.

19 Oct 2015

Envisia's ENV515 (travoprost XR) meets primary efficacy endpoint in phase 2a glaucoma trial

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported results from its first clinical trial of the Company's lead product candidate, ENV515 (travoprost XR).

6 Oct 2015

ILUVIEN continues to show positive results in Europe

Alimera Sciences Limited, the European subsidiary of Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced the availability of real world data from 28 injections of ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) in Europe, presented in a review paper authored by Fahd Quhill, Consultant Ophthalmologist, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, South Yorkshire, U.K.

28 Sep 2015

Alimera Sciences announces results from ongoing study on ILUVIEN

Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy.

24 Sep 2015

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).

22 Jul 2015

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO).

26 Jun 2015

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

The Johns Hopkins University and Bayer HealthCare have entered into a five-year collaboration agreement to jointly develop new ophthalmic therapies targeting retinal diseases. The goal of the strategic research alliance is to accelerate the translation of innovative approaches from the laboratory to the clinic, ultimately offering patients new treatment options for several retinal diseases.

17 Jun 2015

Medicare physician reimbursement data could be confusing to the public

The Centers for Medicare & Medicaid Services today released to the public data relating to 2013 Medicare payments made to physicians and other providers. In response, the American Academy of Ophthalmology is providing necessary context for the reimbursement data, which in its raw form are often complex and difficult to understand.

2 Jun 2015

Promising preliminary results for AKB-9778 in diabetic macular oedema

AKB-9778, a small molecule competitive inhibitor of vascular endothelial-protein tyrosine phosphatase, has a good safety and efficacy profile in patients with diabetic macular oedema, suggests a preliminary dose-escalation study.

19 May 2015

Envision presents awards for work in low vision rehabilitation

Envision presents the Lifetime Achievement Award from time-to-time to researchers whose careers have been marked by outstanding, creative and important contributions to low vision research...

14 May 2015

Trained nurses administer AMD treatments as safely and effectively as doctors

Nurses trained to deliver eye injections for patients with the wet form of age-related macular degeneration (AMD) administered the treatments as safely and effectively as doctors, according to a new study. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Denver, Colo.

6 May 2015